Surgical Outcomes in Small Cell Lung Cancer.
- Author:
Min Ho JU
1
;
Hyeong Ryul KIM
;
Joon Bum KIM
;
Yong Hee KIM
;
Dong Kwan KIM
;
Seung Il PARK
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Korea. scena@dreamwiz.com
- Publication Type:Original Article
- Keywords:
Lung neoplasms;
Lung surgery;
Carcinoma, oat cell
- MeSH:
Carcinoma, Small Cell;
Chemotherapy, Adjuvant;
Disease Progression;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Lung Neoplasms;
Lymph Node Excision;
Lymph Nodes;
Mastectomy, Segmental;
Neoplasm Metastasis;
Pneumonectomy;
Pneumonia;
Recurrence;
Small Cell Lung Carcinoma;
Survival Rate
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2012;45(1):40-44
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The experience of a single-institution regarding surgery for small cell lung cancer (SCLC) was reviewed to evaluate the surgical outcomes and prognoses. MATERIALS AND METHODS: From July 1990 to December 2009, thirty-four patients (28 male) underwent major pulmonary resection and lymph node dissection for SCLC. Lobectomy was performed in 24 patients, pneumonectomy in eight, bilobectomy in one, and segmentectomy in one. Surgical complications, mortality, the disease-free survival (DFS) rate, and the overall survival rate were analyzed retrospectively. RESULTS: The median follow-up period was 26 months (range, 4 to 241 months), and there was one surgical mortality (2.9%). Six patients (17.6%) experienced recurrence, all of which were systemic. Eight patients died during follow-up; four died of disease progression and the other four died of pneumonia or of another non-cancerous cause. The three-year DFS rate was 79.2+/-2.6% and the overall survival rate was 66.4+/-10.5%. Recurrence or death was significantly prevalent in the patients with lymph node metastasis (p=0.001) as well as in those who did not undergo adjuvant chemotherapy (p=0.008). The three-year survival rate was significantly greater in the patients with pathologic stage I/II cancer than in those with stage III cancer (84% vs. 13%, p=0.001). CONCLUSION: Major pulmonary resection for small cell lung cancer is feasible in selected patients. Patients with pathologic stage I or II disease showed an excellent survival rate after surgery and adjuvant treatment. Prospective randomized studies will be needed to define the role of surgery in early-stage small cell lung cancer.
